| IDH mutation in glioma: molecular mechanisms and potential therapeutic targets S Han, Y Liu, SJ Cai, M Qian, J Ding, M Larion, MR Gilbert, C Yang British journal of cancer 122 (11), 1580-1589, 2020 | 470 | 2020 |
| Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair Y Lu, J Kwintkiewicz, Y Liu, K Tech, LN Frady, YT Su, W Bautista, SI Moon, ... Cancer research 77 (7), 1709-1718, 2017 | 210 | 2017 |
| Evaluating in vitro DNA damage using comet assay Y Lu, Y Liu, C Yang JoVE (Journal of Visualized Experiments), e56450, 2017 | 193 | 2017 |
| Brusatol, an NRF2 inhibitor for future cancer therapeutic SJ Cai, Y Liu, S Han, C Yang Cell & bioscience 9, 1-3, 2019 | 110 | 2019 |
| Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism D Yu, Y Liu, Y Zhou, V Ruiz-Rodado, M Larion, G Xu, C Yang Proceedings of the National Academy of Sciences 117 (18), 9964-9972, 2020 | 104 | 2020 |
| Targeting IDH1-Mutated Malignancies with NRF2 Blockade Y Liu, Y Lu, O Celiku, A Li, Q Wu, Y Zhou, C Yang JNCI: Journal of the National Cancer Institute 111 (10), 1033-1041, 2019 | 84 | 2019 |
| Blockade of Glutathione Metabolism in IDH1-Mutated Glioma X Tang, X Fu, Y Liu, D Yu, SJ Cai, C Yang Molecular cancer therapeutics 19 (1), 221-230, 2020 | 73 | 2020 |
| Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma Y Pang, Y Lu, V Caisova, Y Liu, P Bullova, TT Huynh, Y Zhou, D Yu, ... Clinical Cancer Research 24 (14), 3423-3432, 2018 | 71 | 2018 |
| Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling J Tang, J Zhang, Y Liu, Q Liao, J Huang, Z Geng, W Xu, Z Sheng, G Lee, ... Cancer letters 430, 148-159, 2018 | 55 | 2018 |
| Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis Q Liao, W Liu, Y Liu, F Wang, C Wang, J Zhang, M Chu, D Jiang, L Xiao, ... Oncotarget 6 (37), 40081, 2015 | 53 | 2015 |
| Isocitrate dehydrogenase mutations in glioma: genetics, biochemistry, and clinical indications Y Liu, F Lang, FJ Chou, KA Zaghloul, C Yang Biomedicines 8 (9), 294, 2020 | 51 | 2020 |
| Efficient ADCC- killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK PDM Giles AJ, Hao S, Padget MR, Song H, Zhang W, Lynes J, Sanchez VE, Liu Y ... JCI insight, 2019 | 49 | 2019 |
| Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy Y Lu, Y Liu, Y Pang, K Pacak, C Yang Pharmacology & therapeutics 188, 168-175, 2018 | 49 | 2018 |
| Binding of the monoclonal antibody RP 215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis Y Liu, D Liu, C Wang, Q Liao, J Huang, D Jiang, W Shao, CC Yin, ... Histopathology 67 (5), 645-653, 2015 | 44 | 2015 |
| Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies Y Pang, Y Liu, K Pacak, C Yang Cancers 11 (4), 436, 2019 | 41 | 2019 |
| IgG and IgA with potential microbial-binding activity are expressed by normal human skin epidermal cells D Jiang, J Ge, Q Liao, J Ma, Y Liu, J Huang, C Wang, W Xu, J Zheng, ... International journal of molecular sciences 16 (2), 2574-2590, 2015 | 41 | 2015 |
| Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas V Ruiz-Rodado, TM Malta, T Seki, A Lita, T Dowdy, O Celiku, ... Neuro-oncology 22 (4), 480-492, 2020 | 39 | 2020 |
| IgG is involved in the migration and invasion of clear cell renal cell carcinoma Z Sheng, Y Liu, C Qin, Z Liu, Y Yuan, FZ Hu, Y Du, H Yin, X Qiu, T Xu Journal of Clinical Pathology 69 (6), 497-504, 2016 | 37 | 2016 |
| Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid Y Liu, Y Pang, B Zhu, O Uher, V Caisova, TT Huynh, D Taieb, ... Clinical Cancer Research 26 (14), 3868-3880, 2020 | 35 | 2020 |
| NRF2 in human neoplasm: Cancer biology and potential therapeutic target Y Liu, F Lang, C Yang Pharmacology & therapeutics 217, 107664, 2021 | 34 | 2021 |
Chunzhang YangNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute在 nih.gov 的电子邮件经过验证
